Clareo Health | Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Foundation for Liver Research
With
Erasmus Medical Center
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Cytological or histologically confirmation of pancreatic cancer.
WHO performance status of 0 or 1
ASA classification I or II
Tumor considered locally advanced after diagnostic work-up including CT-imaging and diagnostic laparoscopy.
No evidence of metastatic disease
Largest tumor diameter \< 7 cm x 7 cm x 7 cm
Normal renal function (Creatinine ≥ 30 ml/min).
Normal liver tests (bilirubin \< 1.5 times normal; ALAT/ASAT \< 5 times normal)
Normal bone marrow function (WBC \> 3.0 x 10e9/L, platelets \> 100 x 10e9/L and hemoglobin \> 5.6 mmol/l)
Age \> 18 years and \< 75 years
Written informed consent
You may not be if
Prior radiotherapy, chemotherapy or resection (bypass surgery allowed).
Lymph node metastases from primary tumor outside the field of radiation.
Second primary malignancy except in situ carcinoma of the cervix, adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence.
Pregnancy, breast feeding.
Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
